108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE
Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
Financial Results, Reg. FD
Material Contracts, Unregistered Sales of Equity Securities
Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high Expression (IHC3+) Biliary Tract Cancer
Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Announces Appointment of Oleg Nodelman to Board of Directors
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
RW
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership